77 related articles for article (PubMed ID: 9311620)
21. Pharmacokinetics and bioavailability of cefquinome in healthy piglets.
Li XB; Wu WX; Su D; Wang ZJ; Jiang HY; Shen JZ
J Vet Pharmacol Ther; 2008 Dec; 31(6):523-7. PubMed ID: 19000274
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han KS; Lee MG
Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506
[TBL] [Abstract][Full Text] [Related]
24. Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
Takami H; Koshimura H; Kishibayashi N; Ishii A; Nonaka H; Aoyama S; Kase H; Kumazawa T
J Med Chem; 1996 Dec; 39(26):5047-52. PubMed ID: 8978835
[TBL] [Abstract][Full Text] [Related]
25. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
[TBL] [Abstract][Full Text] [Related]
26. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes.
Hirosumi J; Nakayama O; Fagan T; Sawada K; Chida N; Inami M; Takahashi S; Kojo H; Notsu Y; Okuhara M
J Steroid Biochem Mol Biol; 1995 Apr; 52(4):357-63. PubMed ID: 7734404
[TBL] [Abstract][Full Text] [Related]
27. Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats.
Roumi M; Marleau S; du Souich P; Maggi T; Deghenghi R; Ong H
Drug Metab Dispos; 2000 Jan; 28(1):44-50. PubMed ID: 10611139
[TBL] [Abstract][Full Text] [Related]
28. Toxicokinetics of 2',3'-didehydro-3'-deoxythymidine, stavudine (D4T).
Kaul S; Dandekar KA; Schilling BE; Barbhaiya RH
Drug Metab Dispos; 1999 Jan; 27(1):1-12. PubMed ID: 9884303
[TBL] [Abstract][Full Text] [Related]
29. [Effect of large-dosage of 5alpha-reductase inhibitors on the spermatogenesis of male rats].
Wang XD; Jia Y; Cui YG; Wang XH; Tong JS; Ma DZ; Cai RF; Di FS
Zhonghua Nan Ke Xue; 2005 Sep; 11(9):652-4. PubMed ID: 16209201
[TBL] [Abstract][Full Text] [Related]
30. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
[TBL] [Abstract][Full Text] [Related]
31. Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues.
Tanaka C; Kawai R; Rowland M
Drug Metab Dispos; 2000 May; 28(5):582-9. PubMed ID: 10772639
[TBL] [Abstract][Full Text] [Related]
32. 4-(Benzoylindolizinyl)butyric acids; novel nonsteroidal inhibitors of steroid 5alpha-reductase. III.
Sawada K; Okada S; Kuroda A; Watanabe S; Sawada Y; Tanaka H
Chem Pharm Bull (Tokyo); 2001 Jul; 49(7):799-813. PubMed ID: 11456083
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation.
Singh R; Chen IW; Jin L; Silva MV; Arison BH; Lin JH; Wong BK
Drug Metab Dispos; 2001 Dec; 29(12):1578-87. PubMed ID: 11717177
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone.
Bae SK; Chung WS; Kim EJ; Rhee JK; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2004 Apr; 25(3):127-35. PubMed ID: 15083501
[TBL] [Abstract][Full Text] [Related]
39. Toxicokinetics of lambda-cyhalothrin in rats.
Anadón A; Martínez M; Martínez MA; Díaz MJ; Martínez-Larrañaga MR
Toxicol Lett; 2006 Aug; 165(1):47-56. PubMed ID: 16513299
[TBL] [Abstract][Full Text] [Related]
40. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
Boothe DM; Perkins J
J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
